Sudarshan Pharma Industries Limited

BSE: 543828
Sudarshan Pharma Industries Limited - professional services in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L51496MH2008PLC184997 Incorporated 23 July 2008 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 543828 Public Limited Company professional services
Data last updated
Market Cap
₹844 Cr
SUDARSHAN · BSE
Share Price
₹33.98
+0.53% today
Revenue
₹703 Cr
FY 2025-26 · +39.2% YoY
EBITDA
₹51.32 Cr
Margin 7.3%
Net Profit
₹23.31 Cr
FY 2025-26 · +29.3% YoY
P/E (TTM)
34.8x
P/B 5.3x
Authorised capital
₹35 Cr
Registered with MCA
Paid-up capital
₹25.45 Cr
Issued & subscribed

About Sudarshan Pharma Industries Limited

Data last updated:

Sudarshan Pharma Industries Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the scientific services segment of the professional services sector. It was incorporated on 23 July 2008 and has been in existence for over 18 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L51496MH2008PLC184997. Its GSTIN is 27AAMCS2601L1Z6 (Maharashtra). The company holds 6 GST registrations, of which 4 are active. Its shares are listed on BSE: 543828.

The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹25.45 Cr. It was formerly known as Sudarshan Pharma Industries Private Limited and Sudarshan Speciality Chemsolve Private Limited. It is led by directors including Sachin Vasantrai Mehta (Managing Director) and Hemal Vasantrai Mehta (Managing Director).

Its last annual general meeting (AGM) was held on 25 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 301 3rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹703.06 Cr, a growth of 39.2% compared to the previous year. For the same year it recorded a net profit of ₹23.31 Cr (net margin 3.3%) and EBITDA of ₹51.32 Cr (EBITDA margin 7.3%). The net worth stands at ₹155.1 Cr (up 17.7% YoY). Total assets are valued at ₹441.89 Cr (up 44% YoY).

The company has about 9 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.

The company is associated with 2 brands: Farm2energy and Sudarshan Pharma. As per MCA filings, the company has open charges of ₹324.21 Cr and satisfied charges of ₹104.81 Cr on record. Court records list 14 cases involving the company, including 8 filed by the company and 4 filed against it; 9 cases are pending. The company has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025. Its 10 peer companies in the Chemicals industry (API Manufacturers, Industrial Chemicals) are compared by revenue, 5 larger and 5 smaller; the largest is Kennigton Industries Private Limited with revenue of ₹526.01 Cr. The company has 14 MSME Form 1 returns on record between 2015 and 2024, listing 83 overdue payments to 41 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudarshanpharma.com.

Company Details of Sudarshan Pharma Industries Limited
CIN L51496MH2008PLC184997
Registration Number 184997
Incorporation Date 23 July 2008
ROC Mumbai
Listing Status Listed (BSE: 543828)
Company Status Active
Date of Last AGM 25 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant

Name History of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries has undergone 2 name changes throughout its history. The company was previously known as Sudarshan Pharma Industries Private Limited, and Sudarshan Speciality Chemsolve Private Limited. The current legal name is Sudarshan Pharma Industries Limited.

Company NameStatus
Sudarshan Pharma Industries LimitedCurrent
Sudarshan Pharma Industries Private LimitedPrevious
Sudarshan Speciality Chemsolve Private LimitedPrevious

CIN History of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L51496MH2008PLC184997, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L51496MH2008PLC184997Current
U51496MH2008PTC184997Previous
U51496MH2008PLC184997Previous
Key People
Sachin Vasantrai Mehta Managing Director Hemal Vasantrai Mehta Managing Director Jaya Ankur Singhania Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    sudarshanpharma.com
  • Social Media
    Locked
  • Registered Address
    301 3rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092
  • Industry
    Professional Services, Scientific, Technical, Personal
Comprehensive company report
Sudarshan Pharma Industries Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Sudarshan Pharma Industries Limited report

Financials, compliance, directors, charges, ownership and filings for Sudarshan Pharma Industries Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands with Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries operates two associated brands: Farm2energy and Sudarshan Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Farm2energy
Offers online slot gaming with jackpots and integrated e-commerce features for users.farm2energy.com
Sudarshan Pharma
Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals.sudarshanpharma.com

Business Activity of Sudarshan Pharma Industries Limited

The main business activities of Sudarshan Pharma Industries are trade and professional, scientific and technical. In detail, this covers wholesale trading and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
GTradeG1Wholesale TradingLocked
MProfessional, Scientific and TechnicalM9Other professional, scientific and technical activitiesLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Sudarshan Pharma Industries Limited FY 2025-26 filings available

Sudarshan Pharma Industries Limited reported revenue of ₹703.06 Cr (up 39.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹703 Cr
+39.2% YoY
EBITDA
₹51.32 Cr
+38.3% YoY
Profit After Tax
₹23.31 Cr
+29.3% YoY
Net Worth
₹155 Cr
+17.7% YoY
Total Assets
₹442 Cr
+44.0% YoY
Total Debt
₹285 Cr
+63.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue703505464461357193148
Revenue growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
EBITDA51.3237.1122.8114.6810.927.164.76
EBITDA margin+7.3%+7.4%+4.9%+3.2%+3.1%+3.7%+3.2%
Profit before tax30.5421.6415.249.497.133.571.71
Net profit23.3118.0311.467.215.322.661.27
Net profit margin+3.3%+3.6%+2.5%+1.6%+1.5%+1.4%+0.9%
EPS (₹)0.970.664.762.925.382.801.34
Balance sheet
Total assets44230721713560.4152.3540.66
Net worth15513211210129.7822.5119.84
Total debt28517510534.1030.6029.7720.81
Cash & bank1.130.550.1411.720.241.251.27
Net working capital29122617410152.6240.8629.38
Cash flow
Cash from operations(2.30)(32.32)6.01(28.79)(3.82)2.770.51
Cash from investing(76.29)(20.62)(5.49)(25.65)(1.46)(1.29)(2.53)
Cash from financing79.1753.35(12.10)65.934.26(1.49)(0.28)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue174221168169145162116129
Revenue growth (YoY)+20.1%+36.7%+45.3%+31.3%+46.4%---
Other income1.224.131.521.861.210.840.510.32
EBITDA15.9020.2010.879.2111.0414.287.9811.87
EBITDA margin+9.1%+9.1%+6.5%+5.5%+7.6%+8.8%+6.9%+9.2%
Depreciation1.411.090.910.900.880.830.630.67
Interest8.217.536.285.945.964.404.003.70
Profit before tax7.5015.715.204.235.419.893.867.82
Tax1.904.311.050.361.452.480.961.95
Net profit5.6011.404.153.873.967.412.905.87
EPS (₹)0.230.470.180.160.160.290.120.24
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue668503466461357193148
Revenue growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
EBITDA48.9735.6922.5914.6810.937.284.76
EBITDA margin+7.3%+7.1%+4.9%+3.2%+3.1%+3.8%+3.2%
Profit before tax28.6621.3015.089.497.143.581.71
Net profit21.9717.9811.347.215.332.671.27
Net profit margin+3.3%+3.6%+2.4%+1.6%+1.5%+1.4%+0.9%
EPS (₹)0.900.664.722.935.392.801.34
Balance sheet
Total assets43630821913560.4052.3040.66
Net worth15313111210129.7822.5119.84
Total debt28217710734.1030.5929.7820.81
Cash & bank0.110.390.1311.710.231.151.27
Net working capital28622917310152.5140.7229.38
Cash flow
Cash from operations(2.75)(33.18)9.69(28.79)(3.70)2.670.51
Cash from investing(79.71)(20.24)(9.08)(25.65)(1.54)(1.35)(2.53)
Cash from financing82.1853.68(12.18)65.934.31(1.44)(0.28)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue166200158167142162116124
Revenue growth (YoY)+16.4%+23.7%+37.0%+35.1%+39.9%---
Other income1.353.211.692.091.410.910.570.59
Total expenses149182148157132148108112
EBITDA16.2718.3010.779.6110.2813.567.9611.23
EBITDA margin+9.8%+9.2%+6.8%+5.8%+7.2%+8.4%+6.9%+9.1%
Depreciation1.291.000.810.810.790.760.660.65
Interest8.197.276.246.075.714.444.053.96
Profit before tax8.1413.245.414.825.199.273.827.21
Tax2.103.691.110.431.462.251.081.81

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue174221168169145162116129
Revenue growth (YoY)+20.1%+36.7%+45.3%+31.3%+46.4%---
Other income1.224.131.521.861.210.840.510.32
EBITDA15.9020.2010.879.2111.0414.287.9811.87
EBITDA margin+9.1%+9.1%+6.5%+5.5%+7.6%+8.8%+6.9%+9.2%
Depreciation1.411.090.910.900.880.830.630.67
Interest8.217.536.285.945.964.404.003.70
Profit before tax7.5015.715.204.235.419.893.867.82
Tax1.904.311.050.361.452.480.961.95
Net profit5.6011.404.153.873.967.412.905.87
EPS (₹)0.230.470.180.160.160.290.120.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue703505464461357193148
Revenue growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
Other income8.712.522.611.120.460.380.02
Total expenses652468441447346186143
Employee cost0.003.452.682.081.681.381.50
EBITDA51.3237.1122.8114.6810.927.164.76
EBITDA margin+7.3%+7.4%+4.9%+3.2%+3.1%+3.7%+3.2%
Depreciation3.792.221.240.910.870.740.35
Interest25.7015.778.945.403.383.232.72
Profit before tax30.5421.6415.249.497.133.571.71
Tax7.165.683.782.461.880.910.44
Net profit23.3118.0311.467.215.322.661.27
Net profit margin+3.3%+3.6%+2.5%+1.6%+1.5%+1.4%+0.9%
EPS (₹)0.970.664.762.925.382.801.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0724.0724.0724.079.759.559.55
Reserves & surplus12710487.6476.9120.0312.9610.29
Shareholders' funds (net worth)15513211210129.7822.5119.84
Minority interest1.220.000.000.000.000.050.00
Secured loans22614768.9831.0427.384.3614.70
Unsecured loans59.3827.2335.863.063.2225.416.11
Total debt28517510534.1030.6029.7720.81
Total liabilities44230721713560.4152.3540.66
Assets
Gross block11050.3129.3322.458.497.646.32
Net block10447.5025.5019.896.466.225.64
Capital work in progress3.4422.541.880.010.540.000.00
Investments0.001.6713.8412.340.000.000.04
Inventories21914085.7474.5746.8723.9617.38
Sundry debtors23315312381.5173.4860.3926.87
Cash & bank balances1.130.550.1411.720.241.251.27
Loans & advances37.0532.1431.6430.839.002.031.34
Total current assets49032624019913087.6346.86
Total current liabilities20099.3366.4897.1676.9746.7717.48
Net working capital29122617410152.6240.8629.38
Total assets44230721713560.4152.3540.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.550.1411.720.241.251.273.56
Net cash from operating activities(2.30)(32.32)6.01(28.79)(3.82)2.770.51
Net cash from investing activities(76.29)(20.62)(5.49)(25.65)(1.46)(1.29)(2.53)
Net cash from financing activities79.1753.35(12.10)65.934.26(1.49)(0.28)
Net change in cash0.580.41(11.58)11.48(1.02)(0.01)(2.29)
Closing cash1.130.550.1411.720.241.251.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
EBITDA growth+38.3%+62.7%+55.4%+34.4%+52.5%+50.4%-
PBT growth+41.1%+42.0%+60.6%+33.1%+99.7%+108.8%+9997.0%
Net income growth+29.3%+57.3%+59.0%+35.5%+100.0%+109.5%-
Revenue CAGR (3Y)+15.1%+12.3%+33.8%+46.1%---
EBITDA CAGR (3Y)+51.8%+50.4%+47.1%+45.6%---
Profitability & leverage
Net income margin+3.3%+3.2%+2.5%+1.5%+1.5%+1.4%+0.9%
Return on capital employed-+15.5%+13.7%+15.2%+18.7%+14.6%+10.9%
Return on net worth-+14.8%+10.8%+10.8%+20.1%+12.6%+6.5%
Debt / equity-1.130.650.491.151.191.05
Long-term debt / equity-0.090.110.140.200.290.35
Interest cover54.0745.2041.4539.2233.6350.3161.68
Efficiency & per share
Fixed asset turnover-17.3017.9029.8244.2827.7023.41
Inventory turnover-4.475.787.6010.089.358.51
Debtors turnover-3.574.545.955.334.435.51
EPS (₹)0.970.664.762.925.382.801.34
Dividend per share (₹)0.000.000.000.300.000.000.00
Book value per share (₹)0.005.3046.4241.9630.5423.5820.78
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue166200158167142162116124
Revenue growth (YoY)+16.4%+23.7%+37.0%+35.1%+39.9%---
Other income1.353.211.692.091.410.910.570.59
Total expenses149182148157132148108112
EBITDA16.2718.3010.779.6110.2813.567.9611.23
EBITDA margin+9.8%+9.2%+6.8%+5.8%+7.2%+8.4%+6.9%+9.1%
Depreciation1.291.000.810.810.790.760.660.65
Interest8.197.276.246.075.714.444.053.96
Profit before tax8.1413.245.414.825.199.273.827.21
Tax2.103.691.110.431.462.251.081.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue668503466461357193148
Revenue growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
Other income8.402.882.751.120.460.270.02
Total expenses619467443447346186143
Employee cost0.003.122.542.081.681.381.50
EBITDA48.9735.6922.5914.6810.937.284.76
EBITDA margin+7.3%+7.1%+4.9%+3.2%+3.1%+3.8%+3.2%
Depreciation3.411.311.230.910.870.740.35
Interest25.3015.969.035.403.383.232.72
Profit before tax28.6621.3015.089.497.143.581.71
Tax6.695.413.742.461.880.910.44
Net profit21.9717.9811.347.215.332.671.27
Net profit margin+3.3%+3.6%+2.4%+1.6%+1.5%+1.4%+0.9%
EPS (₹)0.900.664.722.935.392.801.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0724.0724.0724.079.759.559.55
Reserves & surplus12510387.5576.9220.0312.9610.29
Shareholders' funds (net worth)15313111210129.7822.5119.84
Secured loans22414768.9831.4027.3825.7214.70
Unsecured loans58.2229.2637.912.703.214.066.11
Total debt28217710734.1030.5929.7820.81
Total liabilities43630821913560.4052.3040.66
Assets
Gross block99.5045.0324.3622.458.497.646.32
Net block94.2542.3320.5719.896.466.225.64
Capital work in progress3.4422.541.880.010.540.000.00
Investments7.754.8416.9412.440.100.090.04
Inventories20713784.3774.5746.8723.9617.38
Sundry debtors19915212381.5173.4860.3926.87
Cash & bank balances0.110.390.1311.710.231.151.27
Loans & advances38.7535.2731.7830.738.901.991.34
Total current assets44532523919912987.4946.86
Total current liabilities15895.4065.8797.1676.9746.7717.48
Net working capital28622917310152.5140.7229.38
Total assets43630821913560.4052.3040.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.390.1311.710.231.151.273.56
Net cash from operating activities(2.75)(33.18)9.69(28.79)(3.70)2.670.51
Net cash from investing activities(79.71)(20.24)(9.08)(25.65)(1.54)(1.35)(2.53)
Net cash from financing activities82.1853.68(12.18)65.934.31(1.44)(0.28)
Net change in cash(0.28)0.26(11.58)11.48(0.93)(0.11)(2.29)
Closing cash0.110.390.1311.710.231.151.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
EBITDA growth+37.2%+58.0%+53.9%+34.3%+50.1%+52.9%-
PBT growth+34.6%+41.3%+58.9%+32.9%+99.4%+109.4%-47.7%
Net income growth+22.2%+58.6%+57.3%+35.3%+99.6%+110.2%-
Revenue CAGR (3Y)+13.1%+12.1%+34.0%+46.1%+36.9%+29.9%+38.8%
EBITDA CAGR (3Y)+49.4%+48.4%+45.9%+45.6%+36.1%+141.0%+98.4%
Profitability & leverage
Net income margin+3.3%+3.2%+2.4%+1.5%+1.5%+1.4%+0.9%
Return on capital employed-+15.3%+13.6%+15.2%+18.7%+14.6%+12.0%
Return on net worth-+14.8%+10.7%+10.8%+20.1%+12.6%+6.6%
Debt / equity-1.150.660.491.151.190.91
Long-term debt / equity-0.090.110.140.200.360.30
Interest cover55.5346.4242.2839.2233.6049.3961.68
Efficiency & per share
Fixed asset turnover-20.4019.8929.8236.1227.7034.41
Inventory turnover-4.545.867.6010.089.3510.65
Debtors turnover-3.554.555.955.334.435.61
EPS (₹)0.900.664.722.935.392.801.34
Dividend per share (₹)0.000.000.000.300.000.000.00
Book value per share (₹)0.005.3046.3841.9630.5523.5820.78
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sudarshan Pharma Industries Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board of Directors of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries has 7 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sachin Vasantrai Mehta
Also directs: Life Science Chemical Private Limited, Sudarshan Maven Pharma Private Limited, Ratna Lifesciences Private Limited and 5 more
Managing Director23 Jul 200818 Years 2 MonthsCurrent
Jaya Ankur Singhania
Also directs: Avabodha Bharat Legal Advisory & Training LLP, J S Singhania and Co. LLP, Jet Freight Logistics Limited and 5 more
Director27 Dec 20223 Years 9 MonthsCurrent
Hemal Vasantrai Mehta
Also directs: Sudarshan Akshar Speciality Chemicals LLP, Life Science Chemical Private Limited, Sudarshan Maven Pharma Private Limited and 5 more
Managing Director16 Jan 201511 Years 9 MonthsCurrent
Vijay OjhaDirector18 Oct 20251 Years 0 MonthsCurrent
Anil Balkrishna Ghogare
Also directs: Skyvin Healthcare Private Limited, Unique Developers (India) Private Limited, Spa Biotech Pharma Private Limited and 1 more
Director10 Nov 20232 Years 11 MonthsCurrent
Rushabh Prashant Patil
Also directs: Jet Freight Logistics Limited, Nandana Metals and Mining Limited
Director21 Jul 20233 Years 3 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Peer Comparison of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited is compared with the companies closest to it by revenue in the Chemicals industry (API Manufacturers, Industrial Chemicals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sudarshan Pharma Industries Limited this company₹703.06 Cr (FY 2026)••••••••39.2%••••Mumbai, Maharashtra, India
Kennigton Industries Private Limited₹526.01 Cr (FY 2024)••••••••-44.0%••••Mumbai, Maharashtra, India
Nidl Surfactants Private Limited₹520.37 Cr (FY 2025)••••••••100.0%••••New Delhi, Delhi, India
H. V. R. Industries Private Limited₹517.32 Cr (FY 2025)••••••••39.0%••••Delhi, India
Raichem Medicare Private Limited₹515.04 Cr (FY 2025)••••••••-12.0%••••Chicksugur Village, Karnataka, India
Pharmazell (India) Private Limited₹510.27 Cr (FY 2024)••••••••3.0%••••Chennai, Tamil Nadu, India
Luna Chemical Industries Private Limited₹503.1 Cr (FY 2024)••••••••-37.0%••••New Delhi, Delhi, India
Arene Life Sciences Private Limited₹497.82 Cr (FY 2025)••••••••23.0%••••Sangareddy, Telangana, India
Milagro Life Sciences Private Limited₹497.15 Cr (FY 2023)••••••••1347099.0%••••Mumbai, Maharashtra, India
Evonik Catalysts India Private Limited₹491.62 Cr (FY 2025)••••••••6.0%••••Thane, Maharashtra, India
Apac Trade Private Limited₹488.26 Cr (FY 2023)••••••••••••Mumbai, Maharashtra, India

Peers are the five companies nearest above and the five nearest below Sudarshan Pharma Industries by revenue in the Chemicals industry (API Manufacturers, Industrial Chemicals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited is audited by NGST & Associates for the financial year 2024.

NameStatusAppointment DateCessation Date
NGST & AssociatesLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Shareholding Pattern of Sudarshan Pharma Industries Limited

Shareholding for the quarter ended Sep 2026: promoters hold 58.90%, foreign institutional investors hold 19.40%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 21.70%.

Promoters: 58.90%FII (Foreign Institutional): 19.40%Retail & Others: 21.70%
Sep 2026
QUARTER
58.90% Promoters
19.40% FII (Foreign Institutional)
21.70% Retail & Others
Promoter holding - history
Now 58.90% · Sep 2026High 58.90% · Sep 2026Low 57.40% · Dec 2025
56%57%58%59%60%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 57.40%Mar 2026: 57.40%Jun 2026: 57.40%Sep 2026: 58.90%57.40%58.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters58.90%57.40%57.40%57.40%
Public41.10%42.60%42.60%42.60%

Charges & Borrowings of Sudarshan Pharma Industries Limited

Open charges
₹324.21 Cr
Satisfied charges
₹104.81 Cr
Breakdown by lending institutions
Others₹138.01 Cr
Axis Bank Limited₹44.87 Cr
Indian Bank₹35.99 Cr
Karnataka Bank Ltd.₹35.29 Cr
Canara Bank₹35.00 Cr
Others₹35.06 Cr
Latest charge details
DateLenderAmountStatus
27 Aug 2026Others₹20 CrOpen
07 Aug 2026Karnataka Bank Ltd.₹1.99 CrOpen
30 Jul 2026Others₹2 CrOpen
22 Jul 2026Canara Bank₹35 CrOpen
21 Jul 2026Indian Bank₹5.99 CrOpen

Total charge records: 31 View all charges

Deals & Funding of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025.

Total deals
42
Market trades
34
Funding rounds
4
Rights issues
2
IPO
1
Disclosed funding
₹35.1 Cr

Deals on record (5 of 42)

WhenDealAmountParties
Jan 2025Market trade₹5.54 CrBuyer: Setu Securities Private Limited
Seller: Mansi Share and Stock Broking Private Limited
Sep 2024Market trade₹8.18 CrBuyer: Epitome Trading And Investments, Shyamsakha Broking Services Private Limited
Seller: Shyamsakha Broking Services Private Limited , Epitome Trading And Investments
Sep 2024Market trade₹14.78 CrBuyer: Mansi Share and Stock Broking Private Limited , Setu Securities Private Limited , Epitome Trading And Investments, an individual
Seller: Setu Securities Private Limited , Epitome Trading And Investments, Mansi Share and Stock Broking Private Limited
Sep 2024Market trade₹30.02 CrBuyer: Globalworth Securities Limited
Seller: G G Engineering Limited , 2 individuals
Sep 2024Market trade₹5.75 CrBuyer: an individual
Seller: Multiplier Share and Stock Advisors Private Limited
Premium access

Full deal history

All 42 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited has 14 MSME Form 1 returns on record between 2015 and 2024, listing 83 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 41)

SupplierAmount dueDue sinceReported on
M M Solvochem LLP••••••••••••
an individual supplier••••••••••••
Mehk Chemicals Pvt Ltd••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 14 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited has a workforce of 9 employees as of Mar 27, 2025.

Employee count
9
Active EPFO establishments
1
Employee growth
28.57%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries has 3 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

3
Subsidiary companies
Key Subsidiaries
Company NameCINShares Held
Life Science Chemical Private LimitedU21001GJ2023PTC144108-
Sudarshan Pharma Lifescience Private LimitedU24299MH2021PTC357350-
Ratna Lifesciences Private LimitedU74999PN2017PTC168995-

Showing major subsidiaries. Total: 3.

Recent Activity on Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited has 42 board changes on record since 2008: 25 appointments and 17 cessations. The latest: Vinay Kumar Pandey was appointed as Director on 01 May 2026.

Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101400769 was registered on 27 Aug 2026.
Charges
A charge with Karnataka Bank Ltd. amounted to Rs. 1.99 Cr with Charge ID 101367514 was registered on 07 Aug 2026.
Charges
A charge with Others amounted to Rs. 2.00 Cr with Charge ID 101378786 was registered on 30 Jul 2026.
Charges
A charge registered on 21 Dec 2023 via Charge ID 100836512 with Others was fully satisfied on 29 Jul 2026.
Charges
A charge registered on 11 Nov 2021 via Charge ID 100519376 with Others was fully satisfied on 29 Jul 2026.
Charges
A charge registered on 07 Sep 2020 via Charge ID 100372823 with Others was fully satisfied on 29 Jul 2026.
Charges
A charge registered on 10 Jan 2020 via Charge ID 100314117 with Others was fully satisfied on 29 Jul 2026.
Charges
A charge registered on 10 Mar 2017 via Charge ID 100088633 with Others was fully satisfied on 29 Jul 2026.
Charges
A charge with Canara Bank amounted to Rs. 35.00 Cr with Charge ID 101346986 was registered on 22 Jul 2026.
Charges
A charge with Indian Bank amounted to Rs. 5.99 Cr with Charge ID 101372324 was registered on 21 Jul 2026.
Charges
A charge with Others amounted to Rs. 4.00 Cr with Charge ID 101341937 was registered on 30 Jun 2026.
Appointed
Vinay Kumar Pandey was appointed as Director.

86 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Sudarshan Pharma Industries Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Sudarshan Pharma Industries Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries has 6 GST registrations: 4 active and 2 cancelled or inactive.

Total GSTINs
6
Active
4
Cancelled / inactive
2
GSTINStateStatusRegistered on
27AAMCS2601L1Z6MaharashtraActive01 Jul 2017
24AAMCS2601L1ZCGujaratActive01 Jul 2017
05AAMCS2601L1ZCUttarakhandActive26 Nov 2022
06AAMCS2601L1ZAHaryanaActive07 Nov 2024
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Sudarshan Pharma Industries Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Related news about Sudarshan Pharma Industries Limited

Frequently Asked Questions about Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries is an active public limited company based in Mumbai, Maharashtra, India. The company works in scientific, within the professional services industry. It was incorporated on 23 July 2008 (18+ years old) and is registered under CIN L51496MH2008PLC184997. Listed on BSE: 543828.

Sudarshan Pharma Industries reported revenue of ₹703.06 Cr for FY 2025-26 (up 39.2% YoY) based on consolidated financials.

Sudarshan Pharma Industries has 7 current directors:

The GSTIN of Sudarshan Pharma Industries is 27AAMCS2601L1Z6, registered in Maharashtra. The company has 6 GST registrations in all, of which 4 are active and 2 are cancelled or inactive. Other active GSTINs include 24AAMCS2601L1ZC (Gujarat), 05AAMCS2601L1ZC (Uttarakhand), 06AAMCS2601L1ZA (Haryana).

The CIN (Corporate Identification Number) of Sudarshan Pharma Industries is L51496MH2008PLC184997. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Sudarshan Pharma Industries is listed on BSE with code 543828.

Sudarshan Pharma Industries has 14 court cases on record: 8 filed by the company and 4 filed against it. 9 are pending. Most are in the district courts.

Sudarshan Pharma Industries was incorporated on 23 July 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.

Sudarshan Pharma Industries has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025.

The peers of Sudarshan Pharma Industries by revenue are Kennigton Industries Private Limited, Nidl Surfactants Private Limited, H. V. R. Industries Private Limited, Raichem Medicare Private Limited, Pharmazell (India) Private Limited and 5 more, all in the Chemicals industry (API Manufacturers, Industrial Chemicals).

Vinay Kumar Pandey was appointed as Director on 01 May 2026. Umesh Luthra ceased to be Director on 18 Oct 2025. Vijay Ojha was appointed as Director on 18 Oct 2025. Sudarshan Pharma Industries has 42 board changes on record in total.

Sudarshan Pharma Industries has 14 MSME Form 1 returns on record between 2015 and 2024, listing 83 overdue payments to 41 micro and small suppliers. The latest return was filed on 30 Apr 2024.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available